Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis

Shuyue CAI; Quan XIE; Yuxuan ZHOU; Qingzhu LIU; Ling QIU; Jianguo LIN

doi:10.19401/j.cnki.1007-3639.2025.02.012

您当前的位置：

首页 >

文章列表页 >

Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis

Review | 更新时间：2025-12-31

- Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis
- China Oncology Vol. 35, Issue 2, Pages: 249-254(2025)
- 作者机构：
  
  1. 南京医科大学药学院，江苏南京 211166
  2. 国家卫生健康委员会核医学重点实验室，江苏省分子核医学重点实验室，江苏省原子医学研究所，江苏无锡 214063
- 作者简介：
- 基金信息：
  
  National Natural Science Foundation of China(22076069)
- DOI：10.19401/j.cnki.1007-3639.2025.02.012
  CLC： R737.9
- Received：01 October 2024，
  
  Revised：2024-12-28，
  
  Published：28 February 2025
- 稿件说明：
移动端阅览
Shuyue CAI, Quan XIE, Yuxuan ZHOU, et al. Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis[J]. China Oncology, 2025, 35(2): 249-254.
DOI：

Shuyue CAI, Quan XIE, Yuxuan ZHOU, et al. Latest progress and prospect of NRP-1 targeted molecular probes for breast cancer diagnosis[J]. China Oncology, 2025, 35(2): 249-254. DOI： 10.19401/j.cnki.1007-3639.2025.02.012.

摘要

乳腺癌是全球女性最常见的恶性肿瘤，其中三阴性乳腺癌（triple-negative breast cancer，TNBC）具有高度侵袭性与转移性，近年其发病率逐步上升并呈年轻化趋势。随着对乳腺癌分子机制的深入研究，神经毡蛋白-1（neuropilin-1，NRP-1）作为一种跨膜蛋白，被证实与乳腺癌特别是TNBC的转移及患者预后密切相关，已经成为乳腺癌诊断和治疗的潜在靶点。利用核医学、光学及多模态等成像技术可以无创、实时、精准地检测NRP-1的表达和分布，对于乳腺癌的早期诊断、分期以及治疗和疗效监测具有重要的指导意义。核医学探针将放射性核素（如

Ga、

99m

Tc等）与特定的靶向配体结合，从而特异性靶向肿瘤细胞或组织，并通过正电子发射体层成像（positron emission tomography，PET）或单光子发射计算机体层成像（single photon emission computed tomography，SPECT）实现对乳腺癌的灵敏特异性诊断。随着医学影像及各交叉学科的发展，靶向NRP-1的多模态分子探针[

]

Ga-NODAGA-K(Cy5)DKPPR将PET的高灵敏度和近红外荧光（near-infrared fluorescence，NIRF）的高分辨率优势相结合，实现乳腺癌术前精确诊断并在术中提供实时荧光导航，有助于更准确地识别和切除肿瘤。本文对NRP-1靶向分子探针在乳腺癌诊断中的优缺点进行系统比较，并阐述各类探针在乳腺癌诊疗领域的适用范围及最新研究进展，以期为乳腺癌靶向分子探针的研发及临床应用提供参考。

Abstract

Breast cancer is one of the most prevalent malignant tumor in women worldwide

in which

triple-negative breast cancer (TNBC) is highly invasive and metastatic. In recent years

the incidence rate of TNBC has gradually increased and shown a trend of younger age. With the in-depth research on the molecular mechanism of breast cancer

neuropilin-1 (NRP-1)

a transmembrane protein

has been found to be associated with metastasis and prognosis of breast cancer

particularly TNBC. Therefore

NRP-1 has become a promising target for the diagnosis and treatment of breast cancer. The expression and

distribution of NRP-1 in breast cancer can be detected by nuclear medicine

optical imaging and multimodal imaging methods in a non-invasive

real-time and accurate manner

which has significant application value in the early diagnosis

staging

treatment

and prognosis evaluation of breast cancer. Nuclear medicine probes specifically target tumor cells or tissues by combining radionuclides (e.g.

Ga and

99m

Tc) with specific molecular ligands

and the signal is captured using positron emission tomography (PET) or single-photon emission computed tomography (SPECT)

allowing for sensitive diagnosis of breast cancer. With the development of medical imaging and other interdisciplinary subjects

the NRP-1 targeted multimodal molecular probe [

]

Ga-NODAGA-K(Cy5)DKPPR combined the high sensitivity of PET with the high resolution advantage of near-infrared fluorescence (NIRF) to achieve precise diagnosis of breast cancer and provide real-time fluorescence navigation during surgery

enhancing the accuracy of tumor tissue identification and excision. In this paper

the advantages and disadvantages of NRP-1 targeted molecular probes in the diagnosis of breast cancer were systematically compared

and the application scope and latest research progress of various probes in the diagnosis and treatment of breast cancer were described

in order to provide reference for the development and clinical application of breast cancer targeted molecular probes.

关键词

Keywords

references

CIFUENTES C , OESTE C L , FERNÁNDEZ-PISONERO I , et al . Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer [J ] . Mol Cancer , 2024 , 23 ( 1 ): 142 .

LI C Y , WANG W H , LEUNG C H , et al . KDM5 family as therapeutic targets in breast cancer: pathogenesis and therapeutic opportunities and challenges [J ] . Mol Cancer , 2024 , 23 ( 1 ): 109 .

曹晓珊 , 杨蓓蓓 , 丛斌斌 , 等 . 三阴性乳腺癌脑转移治疗的研究进展 [J ] . 中国癌症杂志 , 2024 , 34 ( 8 ): 777 - 784 . DOI: 10.19401/j.cnki.1007-3639.2024.08.007 http://doi.org/10.19401/j.cnki.1007-3639.2024.08.007

CAO X S , YANG B B , CONG B B , et al . The progress of treatment for brain metastases of triple-negative breast cancer [J ] . China Oncol , 2024 , 34 ( 8 ): 777 - 784 .

JIANG Z F , OUYANG Q C , SUN T , et al . Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial [J ] . Nat Med , 2024 , 30 ( 1 ): 249 - 256 . DOI: 10.1038/s41591-023-02677-x http://doi.org/10.1038/s41591-023-02677-x

中国抗癌协会乳腺癌专业委员会, 中国抗癌协会国际医疗交流分会, 中国医师协会肿瘤医师分会乳腺癌学组 . 中国晚期三阴性乳腺癌临床诊疗指南(2024版) [J ] . 中华肿瘤杂志 , 2024 , 46 ( 6 ): 471 - 480 .

Society of Breast Cancer China Anti-Cancer Association; International Medical Exchange Society, China Anti-Cancer Association; Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association . Guidelines for clinical diagnosis and treatment of advanced triple-negative breast cancer in China (2024 edition) [J ] . Chin J Oncol , 2024 , 46 ( 6 ): 471 - 480 .

SAAVEDRA C , GION M , CORTÉS J , et al . Top advances of the year: breast cancer [J ] . Cancer , 2023 , 129 ( 12 ): 1791 - 1794 . DOI: 10.1002/cncr.34752 http://doi.org/10.1002/cncr.34752

ADRADA B E , MOSELEY T W , KAPOOR M M , et al . Triple-negative breast cancer: histopathologic features, genomics, and treatment [J ] . Radiographics , 2023 , 43 ( 10 ): e230034 .

STOUT N K , MIGLIORETTI D L , SU Y R , et al . Breast cancer screening using mammography, digital breast tomosynthesis, and magnetic resonance imaging by breast density [J ] . JAMA Intern Med , 2024 , 184 ( 10 ): 1222 - 1231 .

SAVVA K V , MACKENZIE A , COOMBES R C , et al . An original study assessing biomarker success rate in breast cancer recurrence biomarker research [J ] . BMC Med , 2024 , 22 ( 1 ): 307 . DOI: 10.1186/s12916-024-03460-6 http://doi.org/10.1186/s12916-024-03460-6

GE S S , JIA T T , SHI J Y , et al . A cutting-edge 68 Ga-labeled bicyclic peptide PET molecular probe for noninvasive assessment of Nectin4 expression [J ] . Bioorg Chem , 2024 , 152 : 107745 .

GOMEZ K , DURAN P , TONELLO R , et al . Neuropilin-1 is essential for vascular endothelial growth factor A-mediated increase of sensory neuron activity and development of pain-like behaviors [J ] . Pain , 2023 , 164 ( 12 ): 2696 - 2710 . DOI: 10.1097/j.pain.0000000000002970 http://doi.org/10.1097/j.pain.0000000000002970

AL-ZEHEIMI N , GAO Y , GREER P A , et al . Neuropilin-1 knockout and rescue confirms its role to promote metastasis in MDA-MB-231 breast cancer cells [J ] . Int J Mol Sci , 2023 , 24 ( 9 ): 7792 .

CONTE C , LONGOBARDI G , BARBIERI A , et al . Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer [J ] . Int J Pharm , 2023 , 633 : 122618 .

THOMAS L , LOW S , HANSEN G L , et al . BI-Y, an neuropilin-1 antagonist, enhances revascularization and prevents vascular endothelial growth factor-a induced retinal hyperpermeability in rodent models of retinopathies [J ] . J Pharmacol Exp Ther , 2023 , 385 ( 3 ): 214 - 221 .

CHEN Y H , GIALELI C , SHEN J Y , et al . Identification of an osteopontin-derived peptide that binds neuropilin-1 and activates vascular repair responses and angiogenesis [J ] . Pharmacol Res , 2024 , 205 : 107259 .

CECI C , RUFFINI F , FALCONI M , et al . Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: a novel strategy to reduce melanoma metastatic potential [J ] . Biomed Pharmacother , 2024 , 176 : 116766 .

WANG Y , ZHANG L , SUN X L , et al . NRP1 contributes to stemness and potentiates radioresistance via WTAP-mediated m6A methylation of Bcl-2 mRNA in breast cancer [J ] . Apoptosis , 2023 , 28 ( 1/2 ): 233 - 246 .

LI Y Y , FENG Q Q , GAO Q , et al . PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis [J ] . Biomed Pharmacother , 2024 , 178 : 117264 .

MA X , LIU H N , SHI C C , et al . Bioinformatics analysis and clinical significance of NRP-1 in triple-negative breast cancer [J ] . Heliyon , 2024 , 10 ( 5 ): e27368 .

PUSZKO A K , SOSNOWSKI P , HERMINE O , et al . Structure-activity relationship studies and biological properties evaluation of peptidic NRP-1 ligands: investigation of N-terminal cysteine importance [J ] . Bioorg Med Chem , 2023 , 94 : 117482 .

李润尚 , 李林法 . 肿瘤分子影像探针的研究进展 [J ] . 中国肿瘤 , 2024 , 33 ( 10 ): 862 - 870 .

LI R S , LI L F . Research progress on molecular imaging probes of malignant tumors [J ] . China Cancer , 2024 , 33 ( 10 ): 862 - 870 .

LIU Q Z , CAI S Y , YE J C , et al . Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo [J ] . Eur J Nucl Med Mol Imaging , 2024 , 51 ( 7 ): 1826 - 1840 .

SU H X , ZHAO L Z , YU B H , et al . Preparation and bioevaluation of [ 99m Tc ] Tc-labeled A7R and D A7R for SPECT imaging of triple-negative breast cancer [J ] . New J Chem , 2022 , 46 ( 44 ): 21401 - 21408 .

CHEN G , HE P B , MA C , et al . Biodegradable ICG-conjugated germanium nanoparticles for in vivo near-infrared dual-modality imaging and photothermal therapy [J ] . ACS Appl Mater Interfaces , 2024 , 16 ( 44 ): 59752 - 59764 .

QIN S , LIU Q Z , LI K , et al . Neuropilin 1-targeted near-infrared fluorescence probes for tumor diagnosis [J ] . Bioorg Med Chem Lett , 2023 , 84 : 129196 .

邹志凤 , 高晶 , 来旖 , 等 . 主动靶向近红外二区诊疗一体化纳米颗粒用于三阴性乳腺癌的研究 [J ] . 分析化学 , 2022 , 50 ( 6 ): 912 - 923 .

ZOU Z F , GAO J , LAI Y , et al . Tumor-targeted theranostic probe for near infrared Ⅱ window fluorescence imaging and anticancer therapy of triple-negative breast cancer [J ] . Chin J Anal Chem , 2022 , 50 ( 6 ): 912 - 923 .

XUE X , LI Q Y , ZHANG P J , et al . PET/NIR fluorescence bimodal imaging for targeted tumor detection [J ] . Mol Pharm , 2023 , 20 ( 12 ): 6262 - 6271 .

ZHAO X Y , ZHANG G J , CHEN J L , et al . A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging [J ] . Eur J Nucl Med Mol Imaging , 2024 , 51 ( 6 ): 1593 - 1604 .

MOUSSARON A , JOUAN-HUREAUX V , COLLET C , et al . Preliminary study of new gallium-68 radiolabeled peptide targeting NRP-1 to detect brain metastases by positron emission tomography [J ] . Molecules , 2021 , 26 ( 23 ): 7273 .

YAO L L , LI Y S , CHEN H J , et al . Dual targeting of integrin α v β 3 and neuropilin-1 receptors improves micropositron emission tomography imaging of breast cancer [J ] . Mol Pharm , 2022 , 19 ( 5 ): 1458 - 1467 .

FENG G K , LIU R B , ZHANG M Q , et al . SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide [J ] . J Control Release , 2014 , 192 : 236 - 242 .

YU B H , SU H X , ZHAO L Z , et al . 99m Tc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer [J ] . Front Bioeng Biotechnol , 2022 , 10 : 1001899 .

LI X Y , YAN N , WU Y Y , et al . Neuropilin-1-targeted nanomedicine for spatiotemporal tumor suppression through photodynamic vascular damage and antiangiogenesis [J ] . ACS Appl Mater Interfaces , 2024 , 16 ( 17 ): 21709 - 21721 .

SCHWENCK J , SONANINI D , COTTON J M , et al . Advances in PET imaging of cancer [J ] . Nat Rev Cancer , 2023 , 23 ( 7 ): 474 - 490 .

NANNI C , FAROLFI A , CASTELLUCCI P , et al . Total body positron emission tomography/computed tomography: current status in oncology [J ] . Semin Nucl Med , 2025 , 55 ( 1 ): 31 - 40 .

SHABSIGH M , SOLOMON L A . Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine [J ] . Chem Biomed Imaging , 2024 , 2 ( 9 ): 615 - 630 .

LU L , CHEN H Y , HAO D K , et al . The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems [J ] . Asian J Pharm Sci , 2019 , 14 ( 6 ): 595 - 608 . DOI: 10.1016/j.ajps.2019.04.004 http://doi.org/10.1016/j.ajps.2019.04.004

LIU S Y , XU W J , LI X X , et al . BOIMPY-based NIR-Ⅱ fluorophore with high brightness and long absorption beyond 1 000 nm for in vivo bioimaging: synergistic steric regulation strategy [J ] . ACS Nano , 2022 , 16 ( 10 ): 17424 - 17434 .

WANG M Z , WANG Y , FU Q R . Magneto-optical nanosystems for tumor multimodal imaging and therapy in-vivo [J ] . Mater Today Bio , 2024 , 26 : 101027 .

GU Q S , YANG Z C , CHAO J J , et al . Tumor-targeting probe for dual-modal imaging of cysteine in vivo [J ] . Anal Chem , 2023 , 95 ( 33 ): 12478 - 12486 .

Views

995

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14

Axillary management after neoadjuvant therapy for breast cancer and optimization of sentinel lymph node diagnosis and treatment

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

Department of Laboratory Medicine, Xingtai People’s Hospital

AI问答

⁰